Ultragenyx Pharmaceutical Aktie
40,60
EUR
-1,60
EUR
-3,79
%
42,05
USD
-1,60
USD
-3,67
%
Werbung
Ultragenyx Pharmaceutical Aktie Analyse
11.05.18 | Ultragenyx Pharmaceutical overweight | Barclays Capital | |
21.02.18 | Ultragenyx Pharmaceutical Buy | Stifel, Nicolaus & Co., Inc. | |
05.12.17 | Ultragenyx Pharmaceutical Equal weight | Barclays Capital | |
14.09.17 | Ultragenyx Pharmaceutical Outperform | Wedbush Morgan Securities Inc. | |
08.08.17 | Ultragenyx Pharmaceutical Neutral | H.C. Wainwright & Co. | |
19.04.17 | Ultragenyx Pharmaceutical Neutral | Wedbush Morgan Securities Inc. | |
19.04.17 | Ultragenyx Pharmaceutical Neutral | H.C. Wainwright & Co. |
Werbung